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Characteristics Associated with Differences in Survival among Black and
White Women with Breast Cancer
Abstract
Importance
Difference in breast cancer survival by race is a recognized problem among Medicare beneficiaries.
Objective
To determine if racial disparity in breast cancer survival is primarily attributable to differences in presentation
characteristics at diagnosis or subsequent treatment.
Design, Setting, and Patients
Comparison of 7375 black women 65 years and older diagnosed between 1991 to 2005 and 3 sets of 7375
matched white control patients selected from 99 898 white potential controls, using data for 16 US
Surveillance, Epidemiology and End Results (SEER) sites in the SEER-Medicare database. All patients
received follow-up through December 31, 2009, and the black case patients were matched to 3 white control
populations on demographics (age, year of diagnosis, and SEER site), presentation (demographics variables
plus patient comorbid conditions and tumor characteristics such as stage, size, grade, and estrogen receptor
status), and treatment (presentation variables plus details of surgery, radiation therapy, and chemotherapy).
Main Outcomes and Measures
5-Year survival.
Results
The absolute difference in 5-year survival (blacks, 55.9%; whites, 68.8%) was 12.9% (95% CI, 11.5%-14.5%; P
< .001) in the demographics match. This difference remained unchanged between 1991 and 2005. After
matching on presentation characteristics, the absolute difference in 5-year survival was 4.4% (95% CI,
2.8%-5.8%; P < .001) and was 3.6% (95% CI, 2.3%-4.9%; P < .001) lower for blacks than for whites matched
also on treatment. In the presentation match, fewer blacks received treatment (87.4% vs 91.8%; P < .001),
time from diagnosis to treatment was longer (29.2 vs 22.8 days; P < .001), use of anthracyclines and taxols was
lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other treatment was more frequent
(8.2% vs 7.3%; P = .04). Nevertheless, differences in survival associated with treatment differences accounted
for only 0.81% of the 12.9% survival difference.
Conclusions and Relevance
In the SEER-Medicare database, differences in breast cancer survival between black and white women did not
substantially change among women diagnosed between 1991 and 2005. These differences in survival appear
primarily related to presentation characteristics at diagnosis rather than treatment differences.
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IMPORTANCE Difference in breast cancer survival by race is a recognized problem among
Medicare beneficiaries.
OBJECTIVE To determine if racial disparity in breast cancer survival is primarily attributable to
differences in presentation characteristics at diagnosis or subsequent treatment.
DESIGN, SETTING, AND PATIENTS Comparison of 7375 black women 65 years and older
diagnosed between 1991 to 2005 and 3 sets of 7375 matched white control patients selected
from 99 898 white potential controls, using data for 16 US Surveillance, Epidemiology and
End Results (SEER) sites in the SEER-Medicare database. All patients received follow-up
through December 31, 2009, and the black case patients were matched to 3 white control
populations on demographics (age, year of diagnosis, and SEER site), presentation
(demographics variables plus patient comorbid conditions and tumor characteristics such as
stage, size, grade, and estrogen receptor status), and treatment (presentation variables plus
details of surgery, radiation therapy, and chemotherapy).
MAIN OUTCOMES AND MEASURES 5-Year survival.
RESULTS The absolute difference in 5-year survival (blacks, 55.9%; whites, 68.8%) was 12.9%
(95% CI, 11.5%-14.5%; P < .001) in the demographics match. This difference remained
unchanged between 1991 and 2005. After matching on presentation characteristics, the
absolute difference in 5-year survival was 4.4% (95% CI, 2.8%-5.8%; P < .001) and was 3.6%
(95% CI, 2.3%-4.9%; P < .001) lower for blacks than for whites matched also on treatment. In
the presentation match, fewer blacks received treatment (87.4% vs 91.8%; P < .001), time
from diagnosis to treatment was longer (29.2 vs 22.8 days; P < .001), use of anthracyclines
and taxols was lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other
treatment was more frequent (8.2% vs 7.3%; P = .04). Nevertheless, differences in survival
associated with treatment differences accounted for only 0.81% of the 12.9% survival
difference.
CONCLUSIONS AND RELEVANCE In the SEER-Medicare database, differences in breast cancer
survival between black and white women did not substantially change among women
diagnosed between 1991 and 2005. These differences in survival appear primarily related to
presentation characteristics at diagnosis rather than treatment differences.
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F or 20 years health care investigators in United States havebeen keenly aware of racial disparities in survival amongwomen with breast cancer.1-4 Numerous reports have not
only identified and documented worse outcomes in black pa-
tients with breast cancer5-7 but have suggested potential rea-
sons for the disparities based on differences in screening,5,8,9
presentation,5,10 comorbid conditions on presentation,5,10 tu-
mor biology,5,11,12 stage,5,6 treatment,5,13,14 and socioeco-
nomic status.7,15
This study examined the extent of the racial disparity in
breast cancer survival in the Medicare population, with the
main goal of addressing why the disparity exists. The analy-
sis used matching to compare the entire population of blacks
in the Surveillance, Epidemiology and End Results (SEER)–
Medicare database to 3 white populations individually paired
to the black population to answer questions about the origins
of the racial disparity, specifically, (1) are white women who
present like black women treated in the same way as black pa-
tients, and if not, (2) to what extent does a difference in treat-
ment explain the disparity in survival?
This study also examined the magnitude of the disparity;
whether the disparity changed between the era before intro-
duction of taxanes (1991-1998) and the era after introduction
of taxanes (1999-2005); the relative contributions of presen-
tation at diagnosis, and treatment after presentation, to dif-
ferences in survival experienced by these groups; and how so-
cioeconomic variables relate to the overall disparity.
Methods
Patient Population
The research protocol was approved by the institutional re-
view board of The Children’s Hospital of Philadelphia. We ob-
tained the SEER-Medicare database for the years 1991-2005 for
16 SEER sites throughout the United States. For each patient,
the entire SEER data set16,17 was merged with Medicare Part
A, Part B, outpatient claims, and the Social Security denomi-
nator file, which was updated December 31, 2009, for this data
set, providing a minimum of 4 years of follow-up for all pa-
tients.
For all analyses of trends over time, we analyzed the 12
SEER sites collecting data over the entire span of the study. For
analyses not considering trends over time, we used all 16 sites.
Defining Patient Characteristics
We defined race using the SEER algorithm18 and compared
black or African American with white non-Hispanic and white-
Hispanic together for the primary analysis (results were simi-
lar if only non-Hispanic white patients were used as controls,
because Hispanic white patients comprised only 3.8% of the
total white population and because never more than 4.6% of
any set of matched pairs included Hispanic whites). Patient co-
morbid conditions such as congestive heart failure, diabetes,
past acute myocardial infarction, stroke, hypertension, and 21
other conditions noted in the eAppendix (Supplement) were
defined with International Classification of Diseases, Ninth Re-
vision, Clinical Modification codes19-22 and collected from Medi-
care claims (inpatient, outpatient, and physician bills) during
a 3-month period prior to diagnosis.
Tumor Biology
Patient tumor characteristics, including stage, size, grade, es-
trogen receptor status, number of nodes dissected, and num-
ber of positive nodes, were obtained through the SEER data-
base.
Treatment Variables
We defined treatment based on information from Medicare and
SEER data. Surgery and chemotherapy were defined by bill-
ing codes in the Medicare claims; surgery was classified into
conserving and nonconserving surgery types. Radiation
therapy was determined by billing codes and SEER data. All
definitions are provided in the eAppendix (Supplement).
Statistical Analysis
Matching Methodology
We included all black patients for each match, so the black study
population was constant and fully representative of black pa-
tients in the SEER population. The white population changed
according to the variables used in the match. We created 3
matched analyses, each using 1 white patient and 1 black pa-
tient in each matched pair. The demographics analysis matched
white to black patients on age, year of diagnosis, and SEER site;
the presentation analysis matched pairs of black and white pa-
tients on the demographics variables as well as presentation
characteristics (comorbid conditions and tumor biology [stage,
size, grade, and estrogen receptor status]); and the treatment
analysis matched patients on demographics and presenta-
tion variables as well as relevant treatment variables such as
surgery, radiation therapy, and chemotherapy, as well as in-
dividual types of surgery and chemotherapy.
As has been suggested by Rubin,23-25 matching was per-
formed first, without viewing outcomes. All matching was
implemented using the PROC ASSIGN26 function in SAS, pro-
viding optimal matches that minimize the distance between
cases and controls.27 We used near-fine balance for SEER site
in the treatment match.28-30 This meant that matches were geo-
graphically balanced, with each SEER site contributing al-
most identical numbers of white and black patients (eAppen-
dix [Supplement]).
Matching on patient covariates in the presentation and
treatment matches also included a score predicting black race
(a propensity score), and a risk score based on a Charlson
score.31-34 The propensity scores used for the matches came
from a logistic regression of black vs white race on the vari-
ables to be controlled in the match (eAppendix [Supple-
ment]). Matching on a propensity score tends to balance vari-
ables in the score.27,35,36
Statistical Tests
For each matching variable we verified that the match bal-
anced the variables it intended to balance. We examined the
standardized difference for each matching variable, which is
the mean difference between black and white as a fraction of
the standard deviation (SD) before matching.20,37,38 We aimed
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to achieve standardized differences below 0.1 SDs.20,27,37,38 We
also assessed how closely we achieved balance using 2-sample
randomization tests, specifically the Wilcoxon rank-sum test
for each continuous covariate, Fisher exact test for each bi-
nary covariate, and a single cross-match test for all covariates
in a given match.39 The cross-match test estimates a sum-
mary measure, upsilon (Υ) (range, 0-1), that compares the ac-
tual match to the balance obtained by complete randomiza-
tion. Υ = 0.5 suggests that the match resembled a randomized
trial, indicating a successful match, whereas Υ = 0 signifies that
the covariates always could be used to perfectly separate black
patients from white patients—ie, a totally unsuccessful match—
and Υ > 0.5 signifies better balance on observed covariates than
expected by randomization.
When testing the hypothesis of no difference in out-
comes between the matched black and white patients, the
Wilcoxon sign-rank statistic40 was used for continuous
outcomes, the McNemar statistic41 for binary outcomes,
and the Prentice-Wilcoxon statistic42,43 for survival out-
comes. When modeling survival differences over time, we
used the paired version of the Cox proportional hazards
model.44 We obtained standard errors for the white-black
paired differences in survival utilizing the bootstrap
method.45 White-to-white comparisons were made using
the same methods applied to the exterior match of nonover-
lapping white control groups.42,43,46 P ≤ .05 (2-tailed) was
considered statistically significant. All tests were performed
using SAS version 9.2 for UNIX (SAS Institute Inc)47 or R ver-
sion 2.13.1.48
Results
Quality of Matches: Matching Results
A total of 107 273 patients were newly diagnosed with inva-
sive breast cancer over all 16 sites, including 7375 black pa-
tients and 99 898 white patients from whom control patients
were matched. Table 1 reports the total black population and
3 white populations matched sequentially to the black popu-
lation.
The 3 matched white groups sequentially remove aspects
of the disparity while leaving other aspects in place so as to
develop an understanding of how the disparity occurs. In each
match, the variables controlled in that match were closely bal-
anced, with no standardized difference ever exceeding 0.09
SDs. In a given match, unmatched variables exhibit differ-
ences that reveal aspects of the disparity. For example, among
all black patients with breast cancer, 26% had a diagnosis of
diabetes, whereas whites matched for age, year of diagnosis,
and SEER site had a much lower rate of diabetes (15.3%). The
presentation match then removed the difference in diabetes
and many other characteristics describing patients at the time
of cancer diagnosis; eg, in the presentation match, 25.9% of
whites had diabetes, similar to the rate among blacks. The treat-
ment match also identified whites with a similar rate of dia-
betes as blacks but also controlled for cancer treatment. Simi-
lar matching results for tumor biology and treatment variables
were also achieved.
We checked the simultaneous balance of all matched co-
variates using the cross-match test and its summary measure
Υ.39,49 For each match, the multivariate imbalance in matched
covariates was smaller than expected by random assignment
to groups (P > .99, Υ = 0.98 for demographics; P > .99, Υ = 0.65
for presentation; P > .99, Υ = 0.53 for treatment). Thus, in each
matched sample, using the matched covariates to identify black
and white patients performed no better than chance.
Examining Treatment Differences by Race
Table 1 also reports information on differences in treatment
by race. Overall, 12.6% of black patients did not have evi-
dence of receiving any treatment for their breast cancer, com-
pared with 5.9% of whites (P < .001, black patients vs demo-
graphics-matched white patients). However, even among
whites who presented with the same patient and tumor char-
acteristics as blacks, 8.2% did not have evidence of treatment
(P < .001, blacks vs presentation-matched whites). Similarly,
among those who did receive treatment, mean time from di-
agnosis to treatment was longer among blacks than among de-
mographics-matched whites, 29.2 days vs 22.5 days (P < .001),
and even among whites who presented like blacks, the delay
was 22.8 days (P < .001). Blacks were also more likely to have
very long delays in treatment. Whereas 5.8% of blacks did not
initiate treatment within the first 3 months from diagnosis, only
2.5% of whites who presented like blacks displayed this gap
(P < .001). Chemotherapy was also different for blacks and
whites: 3.7% of blacks received both an anthracycline and a tax-
ane, compared with 5.0% of whites matched to blacks at pre-
sentation (P < .001). Blacks also received breast-conserving sur-
gery without any other treatment more often than
presentation-matched whites (8.2% vs 7.3%, P = .04).
Survival Results
Figure 1 shows the survival of black patients and the corre-
sponding white matched pairs for all 16 SEER sites in patients
diagnosed with breast cancer between 1991 and 2005. Me-
dian follow-up time after diagnosis for censored patients was
7.6 years (interquartile range [IQR], 5.7-10.1) for blacks; 7.8 years
(IQR, 5.8-10.5) for demographics-matched whites; 7.7 years
(IQR, 5.8-10.4) for presentation-matched whites; and 7.6 years
(IQR, 5.6-10.2) for treatment-matched whites. Table 2 reports
the 2- and 5-year survival differences, and median survival
time, for the black and matched white populations. The ab-
solute survival difference between blacks and demographics-
matched whites at 5 years was 12.9% (P < .001).
Figure 1 also shows the white presentation match, repre-
senting white patients who had the age, year of diagnosis, and
SEER site variables in the match but who also were matched
on patient characteristics including comorbid conditions and
tumor characteristics, including, but not limited to, stage, size,
grade, and estrogen receptor status. The absolute difference
in 5-year survival between the presentation-matched white
population and the black total population was 4.4% (P < .001).
We also observed the treatment-matched white popula-
tion, controlling all the variables in the presentation match as
well as specific treatments including type of surgery, radia-
tion therapy, and chemotherapy. The absolute difference in
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Table 1. Quality of Matchesa
Variable
Black Patients
(n = 7375)
Matched White Patients, No. (%)
Treatment Match
(n = 7375)
Presentation Match
(n = 7375)
Demographics Match
(n = 7375)
All Whites
(Unmatched)
(n = 99 898)
Age at diagnosis, mean y 75.7 75.7 75.8 75.7 76.3d
Year of diagnosis, mean 1999.3 1999.3 1999.3 1999.3 1999.0d
CHF 710 (9.6) 654 (8.9) 675 (9.2) 435 (5.9)d 5785 (5.8)d
Diabetes 1917 (26.0) 1931 (26.2) 1908 (25.9) 1130 (15.3)d 12 762 (12.8)d
Stage
I 2340 (31.7) 2282 (30.9) 2380 (32.3) 3359 (45.5)d 45 482 (45.5)d
II 2429 (32.9) 2461 (33.4) 2453 (33.3) 2195 (29.8)d 29 537 (29.6)d
III 800 (10.8) 826 (11.2) 736 (10.0) 507 (6.9)d 6427 (6.4)d
IV 676 (9.2) 676 (9.2) 676 (9.2) 376 (5.1)d 5023 (5.0)d
Missing 1130 (15.3) 1130 (15.3) 1130 (15.3) 938 (12.7)d 13 429 (13.4)d
Grade
I 885 (12.0) 880 (11.9) 951 (12.9) 1304 (17.7)d 18 349 (18.4)d
II 2177 (29.5) 2205 (29.9) 2201 (29.8) 2724 (36.9)d 36 679 (36.7)d
III 2404 (32.6) 2343 (31.8) 2390 (32.4) 1813 (24.6)d 24 421 (24.4)d
IV 144 (2.0) 132 (1.8) 120 (1.6) 106 (1.4)b 1746 (1.7)
Missing 1765 (23.9) 1815 (24.6) 1713 (23.2) 1428 (19.4)d 18 703 (18.7)d
Estrogen receptor positive 3908 (53.0) 3878 (52.6) 3907 (53.0) 4759 (64.5)d 67 035 (67.1)d
Tumor size, cm
3-<4 769 (10.4) 780 (10.6) 725 (9.8) 597 (8.1)d 8098 (8.1)d
≥4 1594 (21.6) 1516 (20.6) 1511 (20.5) 863 (11.7)d 11 616 (11.6)d
Unknown 900 (12.2) 913 (12.4) 911 (12.4) 647 (8.8)d 8652 (8.7)d
Nodes, mean
Removed 7.7 7.5 8.3d 8.3d 8.2d
Positive 1.7 1.6 1.9 1.3d 1.3d
Ratio of nodes positive to
removed
0.16 0.15 0.16 0.11d 0.11d
No treatment 927 (12.6) 927 (12.6) 608 (8.2)d 433 (5.9)d 6487 (6.5)d
Mastectomy only 2221 (30.1) 2285 (31.0) 2239 (30.4) 2364 (32.1)c 32 913 (32.9)d
Breast-conserving surgery
Plus radiation only 1067 (14.5) 1095 (14.8) 1215 (16.5)d 1584 (21.5)d 20 532 (20.6)d
Surgery only (without other
treatment)
608 (8.2) 562 (7.6) 538 (7.3)b 542 (7.3)b 7553 (7.6)b
Chemotherapy
Doxorubicin, no taxane 534 (7.2) 502 (6.8) 561 (7.6) 441 (6.0)c 5341 (5.3)d
Doxorubicin + taxane 273 (3.7) 303 (4.1) 367 (5.0)d 314 (4.3) 3122 (3.1)c
Days from diagnosis to treatment,
of those who received treatment,
mean
29.2 29.0 22.8d 22.5d 22.0d
No treatment in 3 mo, %
Of those who received treatment 1300 (5.8) 1291 (5.6) 780 (2.5)d 579 (2.1)d 8444 (2.1)d
All patients 1300 (17.6) 1291 (17.5) 780 (10.6)d 579 (7.9)d 8444 (8.5)d
Abbreviation: CHF, congestive heart failure.
a The “Variable” column reports the variables controlled in some of the 3
matches but allowed to vary naturally in other matches. The 29 of a total of
140 variables used in the treatment match (which included all the variables in
the study), along with all 140 variables, are described in the eAppendix). The
“black patients” column reports the means for all black patients in the data set.
The “Treatment Match” column reports the means for the closest white match,
namely the treatment match (which also controls for presentation and
demographics variables); the “Presentation Match” column also controls for
demographics variables. The “All Whites (Unmatched)” column reports data
for all whites in the data set, without control for age, year of diagnosis, or SEER
site. Results for each variable that appear to the left of the bold red vertical line
are for variables included in the match designated by the column. For cells to
the left of the line, all P values were nonpaired P values as a test for balance,
using Wilcoxon rank-sum for continuous variables and Fisher exact test for
categorical variables; percentages or rates not displaying a P value designation
imply nonsignificant differences between blacks and whites. Results to the
right of the bold red vertical line are for variables not used in the match
designated by the column. For cells to the right of the line (excluding the “All
Whites” column, which is always nonpaired), all P values were paired values
using Wilcoxon sign-rank for continuous variables and McNemar test for
categorical variables; percentages or rates not displaying a P value designation
imply nonsignificant differences between blacks and whites.
b P < .05.
c P < .01.
d P < .001.
Research Original Investigation Black and White Women With Breast Cancer
392 JAMA July 24/31, 2013 Volume 310, Number 4 jama.com
Downloaded From: http://jamanetwork.com/ by a University of Pennsylvania User  on 07/18/2017
5-year survival between the treatment-matched white popu-
lation and the total black population was 3.6% (P < .001). Com-
paring the 5-year survival for whites who presented like blacks
(ie, the whites matched to blacks on presentation and demo-
graphic variables) with whites who presented and were treated
like blacks (ie, the whites matched to blacks on presentation
and demographic variables as well as treatment variables), the
absolute difference was small (0.81%) but statistically signifi-
cant (P = .04). We further examined the causes of death de-
termined by SEER based on death certificates for the treatment-
matched pairs (eAppendix [Supplement]). Overall, about half
of the deaths at 5 years were cancer related. Furthermore, about
two-thirds of the difference in 5-year mortality between black
and white patients was attributable to cancer-related causes,
and one-third to noncancer causes of death.
Changes in Survival Differences Over Time
Figure 2 shows survival of all black patients and demo-
graphics-matched white patients in pairs of patients diag-
nosed in the era before the introduction of taxanes (pretax-
anes; 1991-1998) and in the era after the introduction of
taxanes (posttaxanes; 1999-2005) for just the 12 SEER sites
that collected data in both periods. Both black and matched
white survival improved slightly between eras, but the
change in the black-white difference was small and not sig-
nificantly different from zero (12.4% in the pretaxanes
period and 12.2% in the posttaxanes period; P = .65). There
also was no significant difference in the difference between
blacks and whites matched on presentation or the treatment
match between the eras before and after introduction of tax-
anes (eAppendix [Supplement]).
Table 2. Breast Cancer Outcomes for All Matchesa
Outcome Measure
Black Patients
(n = 7375)
Matched White Patients
Treatment Match
(n = 7375)
Presentation Match
(n = 7375)
Demographics Match
(n = 7375)
Survival, median
(IQR), mo
74 (71-77) 82 (79-85) 85 (82-88) 108 (104-110)
2-y survival, % (95%
CI)
76.3 (75.3-77.3) 78.1 (77.2-79.1) 79.4 (78.4-80.3) 86.0 (85.2-86.8)
White − black
difference
NA 1.8 (0.7-2.8) 3.1 (1.9-4.3) 9.7 (8.4-11.0)
P value .006 <.001 <.001
No. of deaths 1681 1569 1469 992
5-y survival, % (95%
CI)
55.9 (54.8-57.0) 59.5 (58.3-60.6) 60.3 (59.2-61.4) 68.8 (67.8-69.9)
White − black
difference
NA 3.6 (2.3-4.9) 4.4 (2.8-5.8) 12.9 (11.5-14.5)
P value <.001 <.001 <.001
No. of deaths 3207 2942 2888 2257
Paired Cox model HR,
black:white (95% CI)
NA 1.11 (1.05-1.17) 1.18 (1.12-1.24) 1.54 (1.46-1.62)
P value <.001 <.001 <.001
Abbreviations: HR, hazard ratio; IQR,
interquartile range; NA, not
applicable.
a All P values for differences in
survival between black patients and
matched white patients use the
Prentice-Wilcoxon test. Paired Cox
Model P values use all follow-up
data after diagnosis. All confidence
intervals for white-black survival
differences were based on
bootstrapped standard errors.
Figure 1. Kaplan-Meier Plot for Breast Cancer Survival for the Total Black Study Population and 3 Matched
White Populations Diagnosed Between 1991-2005
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Explaining Differences in Presentation
There were large differences in the way black and white pa-
tients presented. As a secondary analysis we studied differ-
ences in primary care well before diagnosis occurred in black
and matched white populations. Table 3 describes preven-
tive care indicators between 18 months to 6 months prior to
diagnosis of breast cancer in the study’s 3 matched pairs. (See
eAppendix [Supplement] for coding definitions.) For the de-
mographics match, blacks had significantly less evidence of
at least 1 primary care visit50,51 than matched whites (80.5%
vs 88.5%, respectively; P < .001); significantly lower rates of
breast cancer screening (23.5% vs 35.7%; P < .001); and signifi-
cantly lower rates of colon cancer and cholesterol screening.
Smaller differences, still significant, were observed for pre-
sentation and treatment matches.
Examining the Relationship of Estrogen Receptor Status
to the Survival Disparity
In this analysis we have reported the demographics match
using only age, SEER site, and year of diagnosis that served as
our base case for which we compared the role of presentation
and then treatment. Because presentation comprises some
variables that are potentially changeable (such as comorbid
conditions and tumor size at time of diagnosis) and some that
are biological and should not change (such as estrogen recep-
tor status), we also present a secondary matching analysis that
included the demographics matching variables plus estrogen
receptor status (eAppendix [Supplement]). We found that
5-year survival in white patients matched to black patients for
demographics plus estrogen receptor status decreased from
68.8% (95% CI, 67.8%-69.9%) to 67.1% (95% CI, 66.0%-68.1%)
Table 3. Primary and Preventive Care in the 6 to 18 Months Prior to Diagnosis, Across Matches
Measure
Black Patients
(n = 7375)
Matched White Patientsa
Treatment
Match
(n = 7375)
Presentation
Match
(n = 7375)
Demographics
Match
(n = 7375)
Any primary care
No. evaluablee 5546 5388 5168 5546
Primary care, No. (%) 4463 (80.5) 4655 (86.4)b 4496 (87.0)b 4908 (88.5)b
Any breast cancer screening
No. evaluablee 5546 5388 5168 5546
Screened, No. (%) 1304 (23.5) 1596 (29.6)b 1602 (31.0)b 1978 (35.7)b
Any cholesterol screening
No. evaluablee 5546 5388 5168 5546
Screened, No. (%) 1870 (33.7) 2024 (37.6)b 1965 (38.0)b 2116 (38.2)b
Any colon cancer screening
No. evaluablee 5546 5388 5168 5546
Screened, No. (%) 915 (16.5) 1115 (20.7)b 1101 (21.3)b 1313 (23.7)b
aFor each match, pairs were only
assessed if both members of the pair
had 18 months of data to evaluate
prediagnosis variables. This meant
that for this table, we only analyzed
patients who were diagnosed after
age 66.5 years and diagnosed later
than July 1, 1992. The paired P values
are calculated between the black
patients and matched white patients
using McNemar Test.
bP < .001.
Figure 2. Breast Cancer Survival for Blacks and Demographics-Matched Whites for the Era Before
Introduction of Taxanes (Pretaxanes; 1991-1998) and the Era After Introduction of Taxanes
(Posttaxanes; 1999-2005)
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The overall survival difference did not
change (blacks and
demographics-matched whites each
started with N = 2832 in the
pretaxane era and N = 2419 in the
post-taxane era).
Research Original Investigation Black and White Women With Breast Cancer
394 JAMA July 24/31, 2013 Volume 310, Number 4 jama.com
Downloaded From: http://jamanetwork.com/ by a University of Pennsylvania User  on 07/18/2017
(P < .001). Hence, a portion of the survival difference be-
tween the demographics match and the presentation match
was due to differences in estrogen receptor status, and as such
should not be something that better screening or primary care
could directly change, although improved preventive mea-
sures may potentially allow for earlier diagnosis.
Socioeconomic Status
As a final secondary analysis, using the treatment-matched
pairs, we fit a paired Cox model to evaluate the influence of
race before and after adjusting for dual eligibility status for both
Medicare and Medicaid. Without adjustment, the black-vs-
white hazard ratio for death was 1.11 (95% CI, 1.05-1.17)
(P < .001). After adjusting for dual eligibility status, the haz-
ard ratio was 1.02 (95% CI, 0.97-1.09) (P = .41). Using variables
reflecting neighborhood poverty and education (Census 2000,
databased on the patient’s census tract) we observed find-
ings similar to those obtained by adjusting for dual eligibility
(eAppendix [Supplement]).
Discussion
The large racial difference in breast cancer survival from
diagnosis did not change between 1991-1998 and 1999-2005.
Most of the difference is explained by poorer health of black
patients at diagnosis, with more advanced disease, worse
biological features of the disease, and more comorbid con-
ditions. The 5-year survival difference observed with whites
matched for demographics (age, year of presentation, and
SEER site) was 12.9%, or a difference in median survival
time of nearly 3 years, whereas with whites matched for
cancer and comorbid conditions (ie, the presentation
match) the difference was 4.4%, or a median survival differ-
ence of less than 1 year. Compared with whites who both
presented like blacks and were treated like blacks, (ie, the
treatment match), the difference only changed by 3.6%;
hence, treatment differences explained only 0.81% of the
12.9% difference in 5-year survival. Treatment disparities
might matter more if blacks were diagnosed with less
advanced cancers.
The 3.6% remaining racial difference in 5-year survival
after matching on treatment was predominantly can-
cer related (eAppendix [Supplement]). However, given
that racial and income disparities are seen throughout the
US health care system,52 it would have been surprising to
observe a complete elimination of the survival difference by
matching for similar cancer presentation and treatment.
One important strength of our study was that 99 898 white
patients were used as potential controls for 7375 black pa-
tients. This allowed us to achieve very close matches, gener-
ally avoiding the need for model-based analyses. A model fit-
ted to 99 898 whites and 7375 blacks would be a model that
mostly describes what happens to whites.53
There were important limitations to this study. We did
not have chart review to verify our definitions of treatment
coded from Medicare bills or noted in SEER data. Hence, for
example, we could not track the use of tamoxifen, although
other studies have suggested that black patients use
tamoxifen in at least as high a rate as white patients when
they have estrogen receptor–positive tumors.54-57 Neverthe-
less, it is possible that some portion of the residual unex-
plained difference after accounting for presentation and
treatment relates to endocrine therapy not tracked in SEER.
Furthermore, using SEER data we could not define triple-
negative tumors.58 However, triple-negative tumors are
less common in postmenopausal than premenopausal
blacks (14% vs 39%), and postmenopausal blacks and whites
display no difference in their rates of triple-negative
tumors.58
Our results suggest that it may be difficult to eliminate the
racial disparity in survival from diagnosis unless differences
in presentation can be reduced. There is also a disparity in treat-
ment, with blacks receiving treatment inferior to that re-
ceived by whites with similar presentation, but this explains
only a small part of the observed difference in survival. The
disparity in treatment might matter more if the disparity in pre-
sentation were reduced, because blacks would then be diag-
nosed with less advanced disease, for which treatment is more
effective.
Whether better screening for breast cancer would
reduce the disparity in presentation is not known. Our data
provide evidence suggesting that black patients diagnosed
with breast cancer had previously received less adequate
primary care than did white patients in the demographics
match. Also, blacks were diagnosed with more advanced-
stage disease and also with larger tumors. If a woman has
limited primary care, then apart from screening, it may take
longer before she seeks medical attention for a lump in her
breast. Our data cannot distinguish the effects of screening
from the effects of greater access to primary care. Screening
and earlier diagnosis might be ineffective if black patients
and white patients with similar cancer biology as measured
by SEER had very different cancer biology if measured in
much greater detail; however, in our population of elderly
Medicare patients, differences in biology are smaller issues
than in premenopausal patients.
Black patients are diagnosed not only with more ad-
vanced breast cancers but also with more unrelated comor-
bid conditions. Some of the effectiveness of cancer treatment
for blacks may be blunted by other health problems. If the dif-
ferences in comorbid conditions at diagnosis were reduced, it
is possible that the differences in cancer treatment would mat-
ter more for the differences in survival.
Conclusions
In the SEER-Medicare database, racial differences in breast
cancer survival did not substantially change among women
diagnosed between 1991 and 2005. These differences in
survival appear primarily related to presentation character-
istics at diagnosis rather than treatment differences. In
the presence of large racial differences in patient character-
istics at presentation, treatment differences explained
only a small portion of the survival difference, because
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white women who presented like black women (ie, were
matched on demographics and presentation) but who
received treatment similar to that received by white women
fared almost the same as white women who presented like
black women and who were treated in the same way as
black women.
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